lung cancer

Advanced Lung Cancer: Dramatic Improvements in 5-Year Survival Offer New Hope

Stage IV lung cancer was once considered almost hopeless, with very few patients surviving five years. But in the last decade, new treatments have significantly improved those odds. Today, more stage IV lung cancer patients are living longer – some well beyond five years – thanks to breakthroughs like targeted therapies and immunotherapy. This article […]

Advanced Lung Cancer: Dramatic Improvements in 5-Year Survival Offer New Hope Read More »

CASE SELECTION 1: Long-Term Survival with EGFR-TKI-Resistence in Stage 4 NSCLC

In this first collection, we discuss EGFR-TKI-resistant in stage 4 NSCLC. Despite negative prognosis statistics, many patients have achieved long-term survival by undergoing multiple lines of treatment—an option not always explicitly detailed in standard treatment guidelines (You can download FREE HERE). This underscores the importance of self-advocacy and proactive discussions with your doctor to push for personalized treatment plans.

CASE SELECTION 1: Long-Term Survival with EGFR-TKI-Resistence in Stage 4 NSCLC Read More »

UNDERSTANDING DATO-DXd CLINICAL TRIAL RESULTS IN NSCLC

This document summarizes key clinical trial findings for Dato-DXd in non-small cell lung cancer (NSCLC), focusing on results from two studies: the Phase II TROPION-Lung05 and the Phase III TROPION-Lung01 trials. Special attention is given to the outcomes in patients with EGFR-mutated disease, including a deeper analysis of Dato-DXd’s potential role in this molecular subgroup.

UNDERSTANDING DATO-DXd CLINICAL TRIAL RESULTS IN NSCLC Read More »

The Role of ctDNA/MRD Testing in Cancer: Promise, Practice, and Pitfalls

Circulating tumor DNA (ctDNA) and minimal residual disease (MRD) testing are rapidly transforming the landscape of cancer care. By offering a noninvasive window into the molecular status of a patient’s disease, these technologies are enabling earlier detection of recurrence, more precise monitoring of treatment response, and increasingly personalized therapeutic strategies.

The Role of ctDNA/MRD Testing in Cancer: Promise, Practice, and Pitfalls Read More »

Managing PD-1/PD-L1 Immunotherapy Side Effects: Strategies and Patient Insights

PD-1/PD-L1 inhibitors have transformed cancer care, but their immune-activating mechanisms often lead to diverse side effects requiring tailored management. By categorizing these adverse events and pairing them with evidence-based strategies, patients and clinicians can better navigate treatment challenges. Below, we explore common and rare side effects, their clinical presentations, and practical management approaches, enriched with real-world patient experiences.

Managing PD-1/PD-L1 Immunotherapy Side Effects: Strategies and Patient Insights Read More »

Your Guide to Biomarkers and Associated Therapies in NSCLC

The landscape of non-small cell lung cancer (NSCLC) treatment has dramatically evolved with the identification of specific genetic alterations that drive tumor growth. These molecular biomarkers have enabled the development of targeted therapies that significantly improve patient outcomes compared to traditional chemotherapy. This report provides a comprehensive overview of established and emerging biomarkers in NSCLC

Your Guide to Biomarkers and Associated Therapies in NSCLC Read More »